Bioavailability of Sulforaphane from Two Broccoli Sprout Beverages: Results of a Short-term, Cross-over Clinical Trial in Qidong, China

Abstract

One of several challenges in design of clinical chemoprevention trials is the selection of the dose, formulation, and dose schedule of the intervention agent. Therefore, a cross-over clinical trial was undertaken to compare the bioavailability and tolerability of sulforaphane from two of broccoli sprout-derived beverages: one glucoraphanin-rich (GRR) and the other sulforaphane-rich (SFR). Sulforaphane was generated from glucoraphanin contained in GRR by gut microflora or formed by treatment of GRR with myrosinase from daikon (Raphanus sativus) sprouts to provide SFR. Fifty healthy, eligible participants were requested to refrain from crucifer consumption and randomized into two treatment arms. The study design was as follows: 5-day run-in period, 7-day administration of beverages, 5-day washout period, and 7-day administration of the opposite intervention. Isotope dilution mass spectrometry was used to measure levels of glucoraphanin, sulforaphane, and sulforaphane thiol conjugates in urine samples collected daily throughout the study. Bioavailability, as measured by urinary excretion of sulforaphane and its metabolites (in approximately 12-hour collections after dosing), was substantially greater with the SFR (mean ¼ 70%) than with GRR (mean ¼ 5%) beverages. Interindividual variability in excretion was considerably lower with SFR than with GRR beverage. Elimination rates were considerably slower with GRR, allowing for achievement of steady-state dosing as opposed to bolus dosing with SFR. Optimal dosing formulations in future studies should consider blends of sulforaphane and glucoraphanin as SFR and GRR mixtures to achieve peak concentrations for activation of some targets and prolonged inhibition of others implicated in the protective actions of sulforaphane. Cancer Prev Res; 4(3); 384-95. Ó2011 AACR.

Ciliopathy proteins regulate paracrine signaling by modulating proteasomal degradation of mediators

“…SFN has shown no toxic effects in humans and is currently being tested in several anticancer trials (48,49). Should this compound show therapeutic benefit in rodent ciliopathy mod-…”

Sulforaphane treatment of autism spectrum disorder (ASD)

“…Capsules of sulforaphanerich broccoli sprout extracts were maintained at −20°C, and checked periodically microbiologically and for sulforaphane titer (SI Materials and Methods) (8). Indistinguishable placebo capsules contained microcrystalline cellulose.…”

“…Its therapeutic potential is based on its potent activity in transcriptionally up-regulating genes that control mechanisms whereby aerobic cells protect themselves against oxidative stress, inflammation, DNA-damaging electrophiles, and radiation (3,4). Under basal conditions, these protective systems do not operate at maximal capacity but can be induced to higher activity levels by sulforaphane, thus reducing the risks of developing malignancies and other chronic diseases (5)(6)(7)(8)(9)(10). Sulforaphane is now in widespread clinical evaluation (10).…”

Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition

“…Residents of Qidong are at high risk for the development of hepatocellular carcinoma, which was in part due to long-term exposure to aflatoxin-contaminated food, and the airborne carcinogen, phenanthrene (67). An inverse association between the level of sulforaphane metabolites and carcinogenrelated markers, including aflatoxin-DNA adducts, was demonstrated (139).…”